Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: A multicenter experience

Oncology (Switzerland)

Volumn 82, Issue 5, 2012, Pages 249-260

  Zapletalova, D ^a   Andr, N ^e   Deak, L ^d   Kyr, M ^a   Bajciova, V ^a   Mudry, P ^a   Dubska, L ^b,c   Demlova, R ^b,c   Pavelka, Z ^a   Zitterbart, K ^a   Skotakova, J ^a   Husek, K ^a   Martincekova, A ^a   Mazanek, P ^a   Kepak, T ^a   Doubek, M ^a,b   Kutnikova, L ^a   Valik, D ^c   Sterba, J ^a,e  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^d L PASTEUR UNIVERSITY HOSPITAL   (Slovakia)

^e TIMONE HOSPITAL   (France)

Author keywords

Children; Metronomic chemotherapy; Relapsed pediatric solid tumor; Solid tumor; Tumor angiogenesis

Indexed keywords

CELECOXIB; ETOPOSIDE; FENOFIBRATE; ISOTRETINOIN; RETINOIC ACID; TEMOZOLOMIDE; VITAMIN D;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CHEILITIS; CHILD; CONSTIPATION; DIARRHEA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; HYPONATREMIA; INFANT; INFECTION; LEUKOCYTE; LIVER TOXICITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; OUTPATIENT CARE; OVERALL SURVIVAL; PARTIAL THROMBOPLASTIN TIME; PRACTICE GUIDELINE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTHROMBIN TIME; SCHOOL CHILD; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; SOLID TUMOR; STOMATITIS; THROMBOCYTE; TREATMENT PLANNING; TREATMENT RESPONSE; VOMITING;

ADMINISTRATION, METRONOMIC; ADOLESCENT; ADULT; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DACARBAZINE; ETOPOSIDE; EUROPE; FEASIBILITY STUDIES; FEMALE; FENOFIBRATE; HUMANS; INFANT; ISOTRETINOIN; MALE; NEOPLASMS; PYRAZOLES; REGISTRIES; SULFONAMIDES; VITAMIN D; YOUNG ADULT;

EID: 84860160775     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000336483     Document Type: Article

References (35)

1. Steliarova-Foucher E, Stiller C, Kaatsch P, Berrino F, Coebergh JW, Lacour B, Parkin M: Geographical patterns and time trends of cancer incidence and survival among children and adolescents in Europe since the 1970s (the ACCIS project): an epidemiological study. Lancet 2004; 364: 2097-2105. (Pubitemid 39626805)
2. Matthay KK, Villablanca GJ, Seeger CR, Stram OD, Harris ER, Ramsay KN, Swift P, et al: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999; 341: 1165-1173. (Pubitemid 29480654)
3. Gatenby RA: A change of strategy in the war on cancer. Nature 2009; 459: 508-509.
4. André N, Pasquier E: For cancer, seek and destroy or live and let live? Nature 2009; 1460: 324.
5. Huh WW, Skapek SX: Childhood rhabdomyosarcoma: new insight on biology and treatment. Curr Oncol Rep 2010; 12: 402-410.
6. Balamuth NJ, Womer RB: Ewing's sarcoma. Lancet Oncol 2010; 11: 184-192.
7. Kerbel RS, Viloria-Petit A, Klement G, Rak J: 'Accidental' anti-angiogenic drugs: anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 2000; 36: 1248-1257. (Pubitemid 30407012)
8. Hanahan D, Bergers G, Bergsland E: Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000; 105: 1045-1047. (Pubitemid 30217688)
9. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, et al: Continuous low dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105:R15-R24. (Pubitemid 30217701)
10. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 1878-1886. (Pubitemid 30207647)
11. Sterba J, Valik D, Mudry P, Kepak T, Pavelka Z, Bajciova V, Zitterbart K, et al: Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: singlecenter pilot study. Onkologie 2006; 29: 308-313. (Pubitemid 44022404)
12. André N, Rome A, Coze C, Padovani L, Pasquier E, Camoin L, Gentet JC: Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study. Clin Ther 2008; 30: 1336-1340.
13. Ashley DM, Meier L, Kerby T, Zalduondo FM, Friedman HS, Gajjar A, Kun L, et al: Response of recurrent medulloblastoma to lowdose oral etoposide. J Clin Oncol 1996; 14: 1922-1927. (Pubitemid 26185467)
14. Choi LM, Rood B, Kamani N, La Fond D, Packer RJ, Santi MR, Macdonald TJ: Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors. Pediatr Blood Cancer 2008; 50: 970-975. (Pubitemid 351500173)
15. Kieran MW, Turner CD, Rubin JB, Chi SN, Zimmerman MA, Chordas C, Klement G, et al: A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 2005; 27: 573-581. (Pubitemid 41697342)
16. Casanova M, Ferrari A, Bisogno G, Merks JH, De Salvo GL, Meazza C, Tettoni K, et al: Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol. Cancer 2004; 101: 1664-1671. (Pubitemid 39318915)
17. Peyrl A, Chocholous M, Kieran MW, Azizi AA, Prucker C, Czech T, Dieckmann K, Schmook MT, Haberler C, Leiss U, Slavc I: Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors. Pediatr Blood Cancer 2011, DOI: 10.1002/pbc 24006.
18. Sterba J, Pavelka Z, Andre N, Ventruba J, Skotakova J, Bajciova V, Bronisova D, Valik D: Second complete remission of relapsed medulloblastoma induced by metronomic chemotherapy. Pediatr Blood Cancer 2010; 54: 616-617.
19. Pasquier E, Kavallaris M, André N: Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 2010; 7: 455-465.
20. Panigrahy D, Kaipainen A, Huang S, Butterfield CE, Barnes CM, Fannon M, Laforme AM, et al: PPAR-agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci USA 2008; 105: 985-990. (Pubitemid 351282068)
21. Pozzi A, Ibanez MR, Gatica AE, Yang S, Wei S, Mei S, Falck JR, Capdevila JH: Peroxisomal proliferator-activated receptor-alpha-dependent inhibition of endothelial cell proliferation and tumorigenesis. J Biol Chem 2007; 282: 17685-17695. (Pubitemid 47100312)
22. Mamede AC, Tavares SD, Abrantes AM, Trindade J, Maia JM, Botelho MF: The role of vitamins in cancer: a review. Nutr Cancer 2011; 63: 479-494.
23. Banissi C, Ghiringhelli F, Chen L, Carpentier AF: Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother 2009; 58: 1627-1634.
24. Skapek SX, Ferguson WS, Granowetter L, Devidas M, Perez-Atayde AR, Dehner LP, Hoffer FA, Speights R, Gebhardt MC, Dahl GV, Grier HE, Pediatric Oncology Group: Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. J Clin Oncol 2007; 25: 501-506. (Pubitemid 350002955)
25. Smith TJ, Hillner BE: Bending the cost curve in cancer care. N Engl J Med 2011; 364: 2060-2065.
26. Klement GL, Kamen BA: Nontoxic, fiscally responsible, future of oncology: could it be beginning in the Third World? J Pediatr Hematol Oncol 2011; 33: 1-3.
27. Yu AL, Uttenreuther-Fischer MM, Huang CS, et al: Phase I trial of a human mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 1998; 16: 2169-2180. (Pubitemid 28265055)
28. Adamson PC, Matthay KK, O'Brien M, et al: A phase 2 trial of all-trans-retinoic acid in combination with interferon-2a in children with recurrent neuroblastoma or Wilms tumor: a Pediatric Oncology Branch, NCI and Children's Oncology Group study. Pediatr Blood Cancer 2007; 49: 661-665. (Pubitemid 350194431)
29. Andre N, Padovani L, Verschuur A: Metronomic chemotherapy: back to the future! Drug News Perspect 2010; 23: 143-151.
30. Peyrl A, Azizi AA, Reismueller B, Kieran MW, Heinrich M, Czech T, Dieckmann K, Slavc I: Antiangiogenic metronomic chemotherapy for patients with recurrent embryonal and ependymal brain tumors. Neurooncology 2010; 12: 44.
31. Samaritani R, Corrado G, Vizza E, Sbiroli C: Cyclophosphamide 'metronomic' chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer. BMC Cancer 2007; 7: 65.
32. Fontana A, Galli L, Fioravanti A, et al: Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormonerefractory prostate cancer. Clin Cancer Res 2009; 15: 4954-4962.
33. André N, Abed S, Orbach D, Alla CA, Padovani L, Pasquier E, Gentet JC, Verschuur A: Pilot study of a pediatric metronomic 4-drug regimen. Oncotarget 2011; 2: 960-965.
34. Pasquier E, Kieran MW, Sterba J, Shaked Y, Baruchel S, Oberlin O, Kivivuori MS, et al: Moving forward with metronomic chemotherapy: meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology. Transl Oncol 2011; 4: 203-211.
35. Mick R, Crowley JJ, Carroll RJ: Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. Control Clin Trials 2000 21: 343-359. (Pubitemid 30456294)